| (Values in U.S. Thousands) | Dec, 2014 | Sep, 2014 | Jun, 2014 | Mar, 2014 | Dec, 2013 |
| Sales | -9,999,000 | -9,999,000 | -9,999,000 | -9,999,000 | -9,999,000 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -9,999,000 | -9,999,000 | -9,999,000 | -9,999,000 | -9,999,000 |
| Net Income Growth | unch | unch | unch | unch | unch |
Authentic Holdings Inc (AHRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
AtheroNova, Inc. was incorporated in Delaware in 1997. The Company, through AtheroNova operations, engages in the development of pharmaceutical preparations and pharmaceutical intellectual property. It develops intellectual property that uses certain pharmacological compounds principally for the treatment of atherosclerosis, which is the primary cause of cardiovascular diseases. As of December 31, 2012, it has not generated any revenues from the development of interllectual property and is therefore a development stage company.